SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending after its cancer drug ANKTIVA received conditional marketing authorization from the European Commission, expanding its approval to 33 countries and fueling strong community anticipation of a significant short squeeze. The community is actively discussing the drug's potential as a broad cancer treatment and speculating on further global partnerships and upcoming regulatory catalysts.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

FJET is trending amid intense speculative trading fueled by its extremely low float and high short interest, with the community actively debating a potential short squeeze. This is coupled with anticipation for an FAA Space Launch license and broader market excitement for the space sector, notably with ongoing chatter about a future SpaceX IPO.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is seeing strong discussion after beating Q2 revenue and ARR estimates and raising its full-year revenue outlook, yet the stock is down due to a lowered EPS guidance attributed to acquisition and integration costs. The community is debating whether this reflects a healthy long-term investment in AI-driven cybersecurity expansion or a concern over near-term margin pressure in the software sector.

WorldFinancial

WorldFinancial (WLFI) is trending amid a high-profile Mar-a-Lago forum involving financial leaders and new partnership announcements, though it faces a congressional probe into its foreign investments. The community is sharply divided, with some calling it a financial "game changer" while others label it a "pump and dump" or "scam."

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending after its Q4 '25 earnings call signaled renewed management confidence in near-term licensing deals, particularly for Gate-All-Around (GAA) transistors and GaN-on-Si, with executive bonuses now tied to commercial progress. The community is actively discussing a potential valuation reset and short squeeze, fueled by record trading volume and the anticipated impact of ATOM's power-saving semiconductor technology on AI and high-performance computing, though historical investor skepticism persists.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to a recently reported 55% increase in its measured gold and silver mineral resources, further bolstered by positive metallurgical test results and its current debt-free status. The community is highly bullish, emphasizing substantial institutional investment and the broader market's interest in precious metals amid global instability and potential strategic mineral initiatives.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is generating significant buzz due to its community's active pursuit of a major tokenomics redesign, aiming for a revenue-based economic model, and a recent SEC ETF filing for Spot + Staking which could catalyze broader institutional adoption. Investors are eagerly discussing ATOM's high staking rewards and its foundational role as the "Internet of Blockchains," fueling anticipation for a substantial rally amidst broader altcoin market optimism.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as escalating geopolitical tensions between the US and Iran dominate market conversation, with community members actively discussing potential military action and its implications for global crude supply through the critical Strait of Hormuz. Fluctuating reports on ongoing nuclear talks and US military buildup in the region are fueling speculation around an oil 'war premium'.

Invesco DB US Dollar Index Trust - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

UUP is trending as investors react to evolving Federal Reserve rate cut expectations, influenced by recent economic data and geopolitical developments, leading to active debate and positioning around the dollar's near-term strength or weakness as a potential hedge.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is trending following a rapid succession of significant contract wins for its drone defense and autonomous systems, notably securing a deal with the German State Police and forming strategic partnerships for its counter-UAS technology. The community is highly bullish, fueled by short squeeze speculation and growing institutional interest, seeing the company as a key player in the expanding defense technology sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$DCTH I read from X (again) that there were interesting info on the Eye on CHOPIN Study Insights &amp; Personalizing Treatment in MUM last Saturday...  
 
i.e. Chopin results getting published early March.  
https://x.com/Medtechgur23109/status/2022801778249449840 
 
The recording of the event should be available in the Cure in Sight YouTube channel in couple of weeks.

Samu

Humdinger 1966

Thomas Prindle

Scott

One thing that I heard is holding DCTH back is doing HEPZATO first will exclude patients from getting on current clinical trials for Uveal Melanoma Mets. So oncologist are encouraging patients to look at trials first and holding Hepzato back until progression.

X (Formerly Twitter)

Medtechguru on X (formerly Twitter): "One thing that I heard is holding DCTH back is doing HEPZATO first will exclude patients from getting on current clinical trials for Uveal Melanoma Mets. So oncologist are encouraging patients to look at trials fir...

StockTwits Web

Delcath Systems Inc

 I read from X (again) that there were interesting info on the Eye on CHOPIN Study Insights & Personalizing Treatment in MUM last Saturday...  
 
i.e. Chopin results getting published early March.  


 
 
The recording of the event should be available in the Cure in Sight YouTube channel in couple of weeks.

@xcdvfxcvnbxxvsd The money shot per UCLA Dr Padia““Unfair to make combo not available in future trials given the CHOPIN 75% ORR” This is an important point given many trials exclude LDT treatments. Also, need CHOPIN published to eventually get NCCN guidelines to get changed so that combo is given priority over trials

 The money shot per UCLA Dr Padia““Unfair to make combo not available in future trials given the CHOPIN 75% ORR” This is an important point given many trials exclude LDT treatments. Also, need CHOPIN published to eventually get NCCN guidelines to get changed so that combo is given priority over trials